| 6.0739 -0.016 (-0.26%) | 10-09 15:46 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.4 | 1-year : | 7.85 |
| Resists | First : | 6.33 | Second : | 6.72 |
| Pivot price | 6.07  |
|||
| Supports | First : | 5.71 | Second : | 4.75 |
| MAs | MA(5) : | 5.97 |
MA(20) : | 6.09 |
| MA(100) : | 6.41 |
MA(250) : | 7.27 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 35.7 |
D(3) : | 26.1 |
| RSI | RSI(14): 46.1 |
|||
| 52-week | High : | 12.37 | Low : | 4.34 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AURA ] has closed above bottom band by 44.0%. Bollinger Bands are 44.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.15 - 6.18 | 6.18 - 6.21 |
| Low: | 5.63 - 5.68 | 5.68 - 5.72 |
| Close: | 6.02 - 6.09 | 6.09 - 6.15 |
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Thu, 09 Oct 2025
Pattern recognition hints at Aura Biosciences Inc. upside - Weekly Earnings Recap & Capital Protection Trading Alerts - newser.com
Thu, 25 Sep 2025
Owning 43% shares,institutional owners seem interested in Aura Biosciences, Inc. (NASDAQ:AURA), - Yahoo Finance
Wed, 03 Sep 2025
Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - Yahoo Finance
Wed, 03 Sep 2025
Precision Cancer Therapy Developer Aura Biosciences to Present Latest Advances at Global Investment Conference - Stock Titan
Wed, 13 Aug 2025
Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights - Yahoo Finance
Thu, 15 May 2025
Aura Biosciences Launches Public Offering Of Common Stock And Warrants - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 73.4 (%) |
| Shares Short | 2,920 (K) |
| Shares Short P.Month | 2,740 (K) |
| EPS | -1.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.8 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.2 % |
| Return on Equity (ttm) | -55.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.74 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -83 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -3.1 |
| PEG Ratio | 0 |
| Price to Book value | 2.14 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|